Monday, June 11, 2012

Long-Term Bisphosphonates May Be OK for Select Patients

Two words - Anabolic Clinic (sm).
An analysis of long-term bisphosphonate use, evaluating a composite endpoint of both vertebral and nonvertebral fractures in postmenopausal women, showed minimal benefit of continued bisphosphonate treatment beyond 5 years, although some patients at high risk might consider taking these agents longer.

Marcea Whitaker, MD, from the US Food and Drug Administration's (FDA's) Division of Reproductive and Urologic Products, Office of New Drugs, and colleagues, in response to postmarketing reports of rare but serious bisphosphonate-related adverse effects (eg, atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer), conducted a systematic review of long-term bisphosphonate efficacy.
To find out why anabolic substances are better, go here, here and here.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.